公开(公告)号：WO2018140644A1

公开(公告)日：2018-08-02

申请号：PCT/US2018/015314

申请日：2018-01-25

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： PAULOS, Chrystal, M. ,  MAJCHRZAK, Kinga ,  BOWERS, Jacob, S.

IPC: A61K35/17 ,  A61K48/00 ,  A61P29/00 ,  A61P37/02 ,  C07K16/28 ,  C12N15/09

CPC classification number: A61P29/00 ,  A61K35/17 ,  A61P37/02 ,  C12N5/0635 ,  C12N2501/415 ,  C12N2501/727

Abstract: Provided herein are methods for the production of enhanced ICOS-stimulated Thl7 cells by co-stimulation with inducible coactivator (ICOS) and an inhibitor of POK/Akt signaling and/or an inhibitor of Wnt/β-catenin signaling. Further provided are methods for treatment of cancer by administration of the enhanced ICOS-stimulated Thl7cells as an adoptive T cell therapy.

公开(公告)号：WO2017117521A1

公开(公告)日：2017-07-06

申请号：PCT/US2016/069468

申请日：2016-12-30

Applicant: BERKELEY LIGHTS, INC. ,  CHAPMAN, Kevin T. ,  WANG, Xiaohua ,  GUAN, Xiao ,  BRONEVETSKY, Yelena ,  STADLER, Guido K. ,  LEVIEU, Gregory G. ,  MOCCIARO, Annamaria

Inventor： CHAPMAN, Kevin T. ,  WANG, Xiaohua ,  GUAN, Xiao ,  BRONEVETSKY, Yelena ,  STADLER, Guido K. ,  LEVIEU, Gregory G. ,  MOCCIARO, Annamaria

IPC: C12N5/00 ,  C12N5/07 ,  C12N5/071 ,  C12N5/078 ,  C12N5/0783

CPC classification number: C12N5/00 ,  C07K14/4748 ,  C07K14/52 ,  C07K14/55 ,  C12N5/0635 ,  C12N5/0636 ,  C12N2510/00

Abstract: The present disclosure provides methods of preparing tumor infiltrating cells engineered to express a pro-inflammatory polypeptide. The pro-inflammatory polypeptide is expressed from the tumor infiltrating cell to counter a generally immunosuppressive state in and around tumors resulting from an imbalance between the number and activation state of immune effector cells versus those of suppressor cells. Delivering the proinflammatory polypeptide via expression from the TICs, as distinct from systemic administration, reduces side effects from increased inflammation at sides remote from a tumor to be treated.

Abstract translation: 本公开提供了制备工程化表达促炎多肽的肿瘤浸润细胞的方法。 从肿瘤浸润细胞表达促炎性多肽以抵抗免疫效应细胞与抑制细胞的数量和活化状态之间不平衡所导致的肿瘤内和肿瘤周围的通常免疫抑制状态。 通过TICs的表达传递促炎多肽，与全身施用不同，减少了远离要治疗的肿瘤的侧面炎症增加的副作用。

公开(公告)号：WO2015179759A1

公开(公告)日：2015-11-26

申请号：PCT/US2015/032170

申请日：2015-05-22

Applicant: GENZYME CORPORATION ,  PAPOULIS, Andrew

Inventor： PAPOULIS, Andrew ,  MASON, Paul ,  CARTER, Kara ,  JOSEPH, Alexandra ,  HU, Yiding ,  GREGORY, Jill ,  ZHAO, Zhong ,  YEE, Christopher ,  MOHAMUD, Mohamud ,  XIANG, Yibin ,  DANTHI, Sanjay ,  HUANG, Yinyin

IPC: C07D491/107 ,  C07D491/20 ,  C07D498/10 ,  A61K31/438 ,  A61K31/444 ,  A61K31/537 ,  A61P31/12 ,  A61P35/00 ,  A61P37/06

CPC classification number: C07D498/10 ,  C07D491/107 ,  C07D491/20 ,  C12N5/0635 ,  G01N33/5008 ,  G01N33/60

Abstract: The invention features compounds of Formula (I), Formula (I)-A and Formula (I)- B as disclosed herein, as well as methods of synthesis, therapy, diagnostics, and assays.

Abstract translation: 本发明的特征在于本文公开的式（I），式（I）-A和式（I）-B的化合物，以及合成，治疗，诊断和测定方法。

公开(公告)号：WO2015117162A1

公开(公告)日：2015-08-06

申请号：PCT/US2015/014337

申请日：2015-02-03

Applicant: SOUTH DAKOTA STATE UNIVERSITY

Inventor： YOUNG, Alan, John

IPC: C12P21/08 ,  C12N5/12 ,  C12N5/078 ,  C12N5/077 ,  A61K39/145

CPC classification number: C12N5/0635 ,  C07K16/00 ,  C07K16/28 ,  C07K2317/14 ,  C07K2317/75 ,  C12N5/0651 ,  C12N2501/052 ,  C12N2501/998 ,  C12N2502/11 ,  C12N2502/1121 ,  C12N2502/1192 ,  C12N2506/11 ,  G01N33/6854 ,  G01N33/6872 ,  G01N2333/70503 ,  G01N2333/70553

Abstract: The present invention describes methods to produce vaccines and antibodies, which methods including contacting follicular dendritic cells (FDC) with naive B-cells to mimic conditions in the germinal center (CG) in vitro, including methods of enhancing antibody production in hybridoma cells and compositions comprising product of the instant methods.

Abstract translation: 本发明描述了生产疫苗和抗体的方法，包括使卵泡树突状细胞（FDC）与幼稚B细胞在体外接触以模拟生发中心（CG）中的条件，包括增强杂交瘤细胞和组合物中抗体产生的方法 包括即时方法的产品。

公开(公告)号：WO2013158819A3

公开(公告)日：2015-04-16

申请号：PCT/US2013037066

申请日：2013-04-18

Applicant: ST JUDE CHILDRENS RES HOSPITAL

Inventor： HAECKER HANS

IPC: A01N63/00 ,  C12N5/071

CPC classification number: C12N5/0647 ,  C12N5/0635 ,  C12N5/0636 ,  C12N5/0639 ,  C12N5/0642 ,  C12N5/0644 ,  C12N5/0645 ,  C12N2501/10 ,  C12N2501/125 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/30 ,  C12N2501/60 ,  C12N2502/13 ,  C12N2502/1305 ,  C12N2502/1311 ,  C12N2502/1317 ,  C12N2502/1323 ,  C12N2502/1329 ,  C12N2502/1335 ,  C12N2502/1341 ,  C12N2502/1347 ,  C12N2502/1352 ,  C12N2502/1358 ,  C12N2502/1364 ,  C12N2502/137 ,  C12N2502/1376 ,  C12N2502/1382 ,  C12N2502/1388 ,  C12N2502/1394 ,  C12N2506/03 ,  C12N2510/00 ,  C12N2510/04

Abstract: The present invention is a method and kits for generating a homogenous population of hematopoietic progenitor cells capable of differentiating into a hematopoietic cell lineage. Whereas the combination of Homeobox-B8 protein and FMS-like tyrosine kinase 3 ligand generate cells with the potential to differentiate into different myeloid and lymphoid cell types, Homeobox-A7 protein and erythropoietin generate cells with the potential to differentiate into erythropoietic or thrombopoietic cell types.

Abstract translation: 本发明是用于产生能够分化成造血细胞谱系的造血祖细胞的均匀群体的方法和试剂盒。 而Homeobox-B8蛋白和FMS样酪氨酸激酶3配体的组合产生具有分化成不同骨髓和淋巴细胞类型的潜力的细胞，Homeobox-A7蛋白和促红细胞生成素产生具有分化成红细胞生成或血小板生成细胞类型的潜能的细胞 。

公开(公告)号：WO2015000624A1

公开(公告)日：2015-01-08

申请号：PCT/EP2014/060202

申请日：2014-05-19

Applicant: F. HOFFMANN-LA ROCHE AG ,  ROCHE DIAGNOSTICS GMBH ,  ROCHE DIAGNOSTICS OPERATIONS, INC.

Inventor： RITTER, Mirko ,  TOURNAVITI, Styliani

IPC: C12N5/0781 ,  C07K16/28 ,  A61K39/395 ,  A61K38/00

CPC classification number: C12N5/0635 ,  C07K16/44 ,  C07K2317/20 ,  C12N2501/052 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/727 ,  C12N2501/999

Abstract: Herein is reported a cultivation system for cultivating a pool of ovine B-cells or single deposited ovine B-cells in the presence of phorbol myristate acetate (PMA).

Abstract translation: 本文报道了在佛波酯肉豆蔻酸乙酸酯（PMA）的存在下培养绵羊B细胞池或单一沉积的B细胞池的培养系统。

公开(公告)号：WO2014153363A1

公开(公告)日：2014-09-25

申请号：PCT/US2014/031104

申请日：2014-03-18

Applicant: NORTHEASTERN UNIVERSITY

Inventor： SITKOVSKY, Michail V. ,  ABBOTT, Robert Koehler ,  HATFIELD, Stephen Matthew

IPC: A61P37/04

CPC classification number: A61K31/7076 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/55511 ,  C12N5/0635 ,  C12N2501/05

Abstract: Methods and composition for potentiating germinal centers are disclosed herein. The methods include potentiating germinal centers to enhance antibody production in response to a vaccine, to increase antibody titer in response to a vaccine, and to enhance B cell class switching.

Abstract translation: 本文公开了增强生发中心的方法和组合物。 所述方法包括增强生发中心以增加针对疫苗的抗体产生，以增加针对疫苗的抗体效价，并增强B细胞类别切换。

公开(公告)号：WO2013120973A1

公开(公告)日：2013-08-22

申请号：PCT/EP2013/053026

申请日：2013-02-14

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Inventor： DOGAN, Ismail

IPC: C07K16/00 ,  C12N5/0781

CPC classification number: C07K16/00 ,  A01K67/0275 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2217/203 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/01 ,  C12N5/0635 ,  C12N9/78

Abstract: The present invention relates to a method of producing high-affinity antibodies by sorting specifically labelled B cells which have undergone somatic hypermutation. The invention is particularly useful for producing high-affinity antibodies specific for an infectious agent, more particularly for viruses, or for a tumor cell antigen.

Abstract translation: 本发明涉及通过分选经历体细胞超突变的特异性标记的B细胞产生高亲和力抗体的方法。 本发明特别可用于产生对感染因子，特别是病毒或肿瘤细胞抗原特异的高亲和力抗体。

公开(公告)号：WO2013096568A1

公开(公告)日：2013-06-27

申请号：PCT/US2012/070840

申请日：2012-12-20

Applicant: ELWHA LLC

Inventor： HYDE, Roderick A. ,  KINDSVOGEL, Wayne R.

IPC: C12N5/0781

CPC classification number: A61K35/17 ,  A61K39/00 ,  A61K2039/5156 ,  A61K2039/6012 ,  A61K2039/6081 ,  C07K16/00 ,  C07K16/1018 ,  C07K16/109 ,  C07K16/1271 ,  C07K16/3069 ,  C07K16/40 ,  C07K16/44 ,  C07K2317/14 ,  C07K2317/622 ,  C07K2317/76 ,  C12N5/0635 ,  C12N2510/00

Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen. An isolated recombinant cell line includes an isolated B lymphocyte cell line capable of expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and at least one exogenously incorporated nucleic acid encoding at least one secreted immunoglobulin reactive to a second antigen.

Abstract translation: 本文公开了在分离的B淋巴细胞系中产生一种或多种免疫球蛋白的组合物和方法。 分离的细胞系包括能够表达至少一种外源掺入的膜免疫球蛋白的分离的B淋巴细胞细胞系，其对第一抗原具有反应性，并且至少一种内源分泌的免疫球蛋白可与第二抗原反应。 分离的重组细胞系包括能够表达至少一种对第一抗原具有活性的内源膜免疫球蛋白和至少一种外源掺入的编码至少一种与第二抗原反应的分泌的免疫球蛋白的分泌的免疫球蛋白的B淋巴细胞系。

公开(公告)号：WO2013086029A1

公开(公告)日：2013-06-13

申请号：PCT/US2012/068003

申请日：2012-12-05

Applicant: PRIMORIGEN BIOSCIENCES INC.

Inventor： WOODS, Niels-Bjarne ,  RÖNN, Roger ,  GUIBENTIF, Carolina Isabel, Mendes de Matos

IPC: C12N5/0789 ,  A61K35/14

CPC classification number: C12N5/0634 ,  A61K35/14 ,  A61K35/28 ,  A61K2035/124 ,  C12N5/0635 ,  C12N5/0636 ,  C12N5/0646 ,  C12N5/0647 ,  C12N2500/24 ,  C12N2500/38 ,  C12N2501/02 ,  C12N2501/04 ,  C12N2501/065 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/26 ,  C12N2501/385 ,  C12N2501/71 ,  C12N2501/80 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/11 ,  C12N2506/45

Abstract: Compositions and methods that employ various combinations of such factors as retinoic acid signaling inhibitors, antioxidants, BMP4, VEGF, prostaglandin E 2 pathway stimulants, TPO, SCF, FLT-3, EPO, TGFβ1, p38 MAPK inhibitors, beta adrenergic receptor agonists, cell cycle inhibitors, RXR agonists, Cripto, and chromatin remodelers to drive differentiation of pluripotent stem cells towards primitive blood cells. Uses of such primitive blood cells are provided.

Abstract translation: 使用视黄酸信号传导抑制剂，抗氧化剂，BMP4，VEGF，前列腺素E2途径刺激剂，TPO，SCF，FLT-3，EPO，TGFbeta1，p38 MAPK抑制剂，β肾上腺素能受体激动剂，细胞周期的各种组合的组合物和方法 抑制剂，RXR激动剂，Cripto和染色质重组体，以驱动多能干细胞分化为原始血细胞。 提供了这种原始血细胞的使用。